Squamous cell lung cancer: Current landscape and future therapeutic options.

Autor:	Lau SCM; Department of Medical Oncology, Laura & Issac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, Smilow Building 10th Floor, Suite 1001, New York, NY 10016, USA., Pan Y; Department of Medical Oncology, Laura & Issac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, Smilow Building 10th Floor, Suite 1001, New York, NY 10016, USA., Velcheti V; Department of Medical Oncology, Laura & Issac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, Smilow Building 10th Floor, Suite 1001, New York, NY 10016, USA., Wong KK; Department of Medical Oncology, Laura & Issac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, Smilow Building 10th Floor, Suite 1001, New York, NY 10016, USA. Electronic address: kwok-kin.wong@nyulangone.org.
Jazyk:	angličtina
Zdroj:	Cancer cell [Cancer Cell] 2022 Nov 14; Vol. 40 (11), pp. 1279-1293. Date of Electronic Publication: 2022 Oct 20.
DOI:	10.1016/j.ccell.2022.09.018
Abstrakt:	Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with high mortality and a lack of therapies specific to this disease. Although recurrent molecular aberrations are present in LUSCs, efforts to develop targeted therapies against receptor tyrosine kinases, signaling transduction, and cell cycle checkpoints in LUSCs were met with significant challenges. The present therapeutic landscape focuses on epigenetic therapies to modulate the expression of lineage-dependent survival pathways and undruggable oncogenes. Another important therapeutic approach is to exploit metabolic vulnerabilities unique to LUSCs. These novel therapies may synergize with immune checkpoint inhibitors in the right therapeutic context. For example, the recognition that alterations in KEAP1-NFE2L2 in LUSCs affected antitumor immune responses created unique opportunities for targeted, metabolic, and immune combinations. This article provides a perspective on how lessons learned from the past influence the current therapeutic landscape and opportunities for future drug development for LUSCs. Competing Interests: Declaration of interests The authors declare no competing interests. Outside of the submitted work, V.V. reports personal fees from Foundation Medicine, BMS, AstraZeneca, Merck, Amgen, and Iteos Therapeutics; K.K.W. is a founder and equity holder of G1 Therapeutics, has sponsored research agreements from MedImmune, Takeda, TargImmune, Bristol-Myers Squibb, Mirati, Merus, Zentalis, and Alkermes, and personal fees and sponsored research agreements from AstraZeneca, Janssen, Pfizer, Novartis, Merck, Ono, and Array. (Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu